Early prediction of neoadjuvant treatment outcome in locally advanced breast cancer using parametric response mapping and radial heterogeneity from breast MRI
- 18 November 2019
- journal article
- research article
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 51 (5) , 1403-1411
Abstract
Background: Early prediction of nonresponse is essential in order to avoid inefficient treatments.Purpose: To evaluate if parametrical response mapping (PRM)‐derived biomarkers could predict early morphological response (EMR) and pathological complete response (pCR) 24–72 hours after initiation of chemotherapy treatment and whether concentric analysis of nonresponding PRM regions could better predict response.Study Type: This was a retrospective analysis of prospectively acquired cohort, nonrandomized, monocentric, diagnostic study.Population: Sixty patients were initially recruited, with 39 women participating in the final cohort.Field Strength/Sequence: A 1.5T scanner was used for MRI examinations.Assessment: Dynamic contrast‐enhanced (DCE)‐MR images were acquired at baseline (timepoint 1, TP1), 24–72 hours after the first chemotherapy (TP2), and after the end of anthracycline treatment (TP3). PRM was performed after fusion of T1 subtraction images from TP1 and TP2 using an affine registration algorithm. Pixels with an increase of more than 10% of their value (PRMdce+) were corresponding nonresponding regions of the tumor. Patients with a decrease of maximum diameter (%dDmax) between TP1 and TP3 of more than 30% were defined as EMR responders. pCR patients achieved a residual cancer burden score of 0.Statistical Tests: T‐test, receiver operating characteristic (ROC) curves, and logistic regression were used for the analysis.Results: PRM showed a statistical difference between pCR response groups (P < 0.01) and AUC of 0.88 for the prediction of non‐pCR. Logistic regression analysis demonstrated that PRMdce+ and Grade II were significant (P < 0.01) for non‐pCR prediction (AUC = 0.94). Peripheral tumor region demonstrated higher performance for the prediction of non‐pCR (AUC = 0.85) than intermediate and central zones; however, statistical comparison showed no significant difference.Data Conclusion: PRM could be predictive of non‐pCR 24–72 hours after initiation of chemotherapy treatment. Moreover, the peripheral region showed increased AUC for non‐pCR prediction and increased signal intensity during treatment for non‐pCR tumors, information that could be used for optimal tissue sampling.Level of Evidence: 1Technical Efficacy Stage: 4J. Magn. Reson. Imaging 2020;51:1403–1411.Keywords
This publication has 34 references indexed in Scilit:
- Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancerBreast Cancer Research and Treatment, 2016
- Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?Annals of Oncology, 2014
- Use of Dynamic Contrast-enhanced MR Imaging to Predict Survival in Patients with Primary Breast Cancer Undergoing Neoadjuvant ChemotherapyRadiology, 2011
- Prediction of Clinicopathologic Response of Breast Cancer to Primary Chemotherapy at Contrast-enhanced MR Imaging: Initial Clinical ResultsRadiology, 2006
- Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5Journal of Clinical Oncology, 2005
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2003
- Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcomeBritish Journal of Cancer, 2003
- A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancerAnnals of Oncology, 1998
- THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTSAnnual Review of Medicine, 1997